On February 15, IBEC organized the round table Personalized medicine and its transfer to society. The event had about 45 attendees and was part of the Barcelona Health Innovation Week, organized by Biocat. It was a dialogue in which experts from different fields shared their perspectives on how personalized medicine is changing the diagnosis and treatment of patients.
The week of February 13 to 16 was held the Barcelona Health Innovation Week. It is a meeting organized by Biocat devoted to innovation, acceleration, technology and transformation in healthcare. Through in-house sessions, online webinars, talks, debates and networks, the event allows healthcare organizations and companies to assert their market and thought leadership, showcase their latest innovations, and connect with their audience.
Within the framework of this event, on Wednesday, February 15, took place the round table Personalized medicine and its transfer to society organized by IBEC. Its objective was to reflect on improving the transfer of technology, knowledge, and products developed in universities and research centers to patients for improving their health.
The event had about 45 attendees and was led by Javier Selva, CEO of CataloniaBio & Health Tech. Through this discussion, experts from different fields were able to share their perspectives on how personalized medicine is changing the way patients are diagnosed and treated.
The speakers had a stimulating debate that allowed them to discuss what they considered personalized medicine from different perspectives: clinical, scientific, political, and business.
Among the invited speakers was Josep Samitier, president of the Catalan Association of Research Entities (ACER) and director of IBEC, who contributed to the table with the vision of researchers.
The other speakers that attended the round table were Isabel Amat, Global Head of Innovation and Pipeline Management of the pharmaceutical company Reig-Jofre; Laia Arnal Arasa, director of business development at the Vall d’Hebron Research Institute (VHIR); Laura Pellisé, coordinator of the AseBio Health working group and director of Policy and Government Affairs of the biotechnology company Amgen; Xavier Aldeguer, general director of the Knowledge Society, Transfer, and Territory of the Catalan Government and Jordi William Carnes, president of the Leitat Technology Centre.
